Biofrontera (STU:AI10) Notes Receivable: €0.00 Mil (As of Mar. 2026)


STU:AI10 Biofrontera Inc STU:AI10
42 GF Score
Price €8.06
GF Value €4.60
! 4 Warning Signs
View Full Analysis

What is Biofrontera Notes Receivable?

Biofrontera STU:AI10 42 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:AI10 with a GF Score™ of 42/100 and a GF Value™ of €4.60. The stock has 4 warning signs investors should review.

Biofrontera's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

Biofrontera Notes Receivable Historical Data

* Premium members only.

The historical data trend for Biofrontera's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera Notes Receivable Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Biofrontera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:AI10
42GF Score
Biofrontera Inc STU:AI10
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Biofrontera (STU:AI10) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biofrontera and its competitors.
Is Biofrontera's Notes Receivable too high?
Biofrontera's current Notes Receivable is €0.00 Mil. Overall, Biofrontera has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Notes Receivable compare to BIOE and APUS?
Biofrontera's Notes Receivable of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Biofrontera and its competitors. Biofrontera's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Biofrontera (STU:AI10) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €4.60, compared to a current price of €8.06 — trading 75.2% above its estimated fair value. The current Notes Receivable is €0.00 Mil. Biofrontera's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Biofrontera (STU:AI10), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (STU:AI10) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of €8.06 is trading 75.2% above its estimated GF Value™ of €4.60.

Key valuation signals for STU:AI10:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €4.60 vs. price of €8.06 (75.2% above fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the STU:AI10 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Other Exchanges BFRI:USA
Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
42GF Score

Get the complete analysis for STU:AI10

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.06
Price
€4.60
GF Value